Latest Whitepapers

As biopharmaceutical companies scale up manufacturing, many are turning to outsourcing for buffer and process liquid preparation. But before making this decision, organizations must carefully weigh up various factors, including manufacturing space, personnel requirements and analytical capabilities.

When assessing PARP enzymatic activity for drug development, each component must be carefully optimized to ensure sensitivity, robustness and reproducibility. This whitepaper explores methods and reagents available to evaluate drug specificity and effectiveness.

This whitepaper describes the technology behind this versatile immunoassay, providing an in-depth exploration of its principles, methodologies and diverse applications.

This whitepaper explores the tools available to characterize antibody binding to Fc receptors, including quantitative assays to support optimization of therapeutic products.

This brochure explores the applications of a real-time metabolic analysis platform for cancer research and cell therapeutics development.

Understanding the mechanisms of human disease requires a multiomic approach; however, legacy multiomic methods require multiple platforms and complex processes with lengthy turnaround times and considerable costs.

This whitepaper explores how transitioning from RUO to cGMP chemicals can mitigate risks, streamline processes and maintain regulatory compliance, ultimately accelerating your journey from lab to clinic.

This article explores key challenges in vaccine development scale up and highlights various strategies for overcoming them.

This article explores major advances in disease modification for illnesses that still lack effective treatments, as well as some challenges and approaches to overcome them.

This whitepaper explores the latest advancements in OOC platforms that can help to efficiently simulate drug toxicity responses.